# Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

> **NCT05156541** · PHASE3 · COMPLETED · sponsor: **SPP Pharmaclon Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Human Papillomavirus Infection
- Anogenital Warts

## Interventions

- **DRUG:** Interferon gamma human recombinant (IFN-G)

## Key facts

- **NCT ID:** NCT05156541
- **Lead sponsor:** SPP Pharmaclon Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-18
- **Primary completion:** 2010-06-30
- **Final completion:** 2010-07-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156541, "Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05156541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*